Can Alpha Lipoic Acid Support Energy Levels and Nerve Health for Long COVID Patients?

Alpha-lipoic acid (ALA), also known scientifically as thioctic acid, is a naturally occurring organosulfur compound that is synthesized primarily within the mitochondria of plants, animals, and humans. In a healthy body, it plays an indispensable role in maintaining cellular vitality and defending against environmental stressors. What makes ALA truly unique among nutritional compounds is its chemical structure. It contains a dithiolane ring, which allows it to be both water-soluble and fat-soluble. This dual solubility is a rare and highly valuable trait in biochemistry, earning ALA the title of the "universal antioxidant."

Because it is both lipid- and water-soluble, ALA is not restricted to specific compartments of the body. It can easily cross the highly selective blood-brain barrier, enter the lipid-rich membranes of nerve cells, and dissolve into the watery cytoplasm inside the cell. Once inside the body, ALA is rapidly reduced into its active metabolite, dihydrolipoic acid (DHLA). Unlike most other antioxidants—such as Vitamin C, which is only active in its reduced state—both the oxidized form (ALA) and the reduced form (DHLA) possess potent, direct free-radical scavenging abilities. This allows the compound to neutralize highly reactive and damaging molecules, including hydroxyl radicals, peroxynitrite, and singlet oxygen, across virtually all cellular tissues.

Furthermore, ALA acts as the "antioxidant of antioxidants." When endogenous antioxidants like Vitamin C, Vitamin E, Coenzyme Q10, and glutathione neutralize a free radical, they become oxidized and depleted. Research shows that DHLA can directly recycle and regenerate these depleted antioxidants, returning them to their active states and massively extending the lifespan of the body's natural defense systems. This continuous recycling loop is essential for maintaining cellular resilience, particularly in tissues that require high amounts of oxygen and energy, such as the brain, heart, and peripheral nervous system.

While its antioxidant properties are profound, ALA's primary biological function in a healthy body is to serve as a mandatory coenzyme in mitochondrial energy metabolism. The mitochondria are the powerhouses of our cells, responsible for converting the food we eat into adenosine triphosphate (ATP), the microscopic currency of cellular energy. Inside the mitochondrial matrix, naturally synthesized lipoic acid is covalently bound to specific proteins to form essential multienzyme complexes that drive the citric acid cycle (also known as the Krebs cycle).

Specifically, ALA is an absolute requirement for the function of two critical enzyme complexes: pyruvate dehydrogenase (PDH) and alpha-ketoglutarate dehydrogenase (AKGDH). The PDH complex is responsible for the oxidative decarboxylation of pyruvate—the end product of glucose breakdown—converting it into acetyl-CoA. This specific biochemical step is the vital bridge that connects glycolysis (the breakdown of sugars) to the Krebs cycle. Without sufficient lipoic acid, this bridge collapses, pyruvate accumulates and ferments into lactic acid, and the mitochondria fail to produce adequate ATP.

Similarly, the AKGDH complex relies on ALA to keep the Krebs cycle turning, ensuring a steady flow of electrons into the electron transport chain. By acting as the essential spark plug for these enzymatic reactions, Alpha Lipoic Acid improves mitochondrial structure and function and elevates cofactors of defective mitochondrial enzymes. In highly metabolically active tissues, such as skeletal muscle and cardiac tissue, a steady supply of ALA is what may help delay premature fatigue and maintains structural integrity during periods of physical or cognitive exertion.

Beyond its direct structural role in the Krebs cycle, Alpha Lipoic Acid functions as a potent metabolic signaling molecule that influences how the entire body manages its fuel supply. One of its most significant systemic effects is the activation of the AMP-activated protein kinase (AMPK) pathway. AMPK is often described as the master metabolic switch or the cellular fuel sensor. When cellular energy levels drop, AMPK is activated to stimulate energy-producing processes (like glucose uptake and fat oxidation) while simultaneously halting energy-consuming processes.

When ALA activates AMPK in skeletal muscles and liver tissue, it triggers a cascade of beneficial metabolic adaptations. It signals the cell to translocate GLUT-4 glucose transporters from the interior of the cell to the outer cell membrane. This allows the cell to pull glucose out of the bloodstream and into the muscle tissue to be burned for fuel. Remarkably, ALA can stimulate this glucose uptake independently of insulin, making it a crucial mechanism for maintaining healthy blood sugar levels, especially in environments where normal insulin signaling has been compromised.

Additionally, the activation of AMPK by Alpha Lipoic Acid subsequently inhibits the mTOR signaling pathway. The suppression of mTOR is a well-documented trigger for cellular autophagy—the biological housekeeping process where cells break down and clear out damaged, misfolded proteins and defective mitochondria. By promoting autophagy, ALA helps ensure that the cellular environment remains clean, efficient, and populated only by healthy, highly functional mitochondria, thereby optimizing the body's overall energy balance and metabolic health.

In complex chronic conditions like Long COVID and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), the body's cellular powerhouses undergo profound, sustained stress. Emerging research indicates that the SARS-CoV-2 virus, and specifically its lingering spike proteins, can directly interact with mitochondrial membranes. This interaction disrupts the delicate balance of mitochondrial dynamics, impairing the processes of fusion and fission, and halting mitophagy—the clearing of damaged mitochondria. The result is an accumulation of swollen, highly inefficient mitochondria that leak reactive oxygen species (ROS) into the cell.

This viral-induced mitochondrial dysfunction creates a catastrophic energy deficit. Because the mitochondria are damaged, the crucial enzyme complexes that rely on Alpha Lipoic Acid (like pyruvate dehydrogenase) become oxidized and functionally impaired. Instead of efficiently converting glucose into ATP through the Krebs cycle, the cells are forced to rely on inefficient, anaerobic glycolysis. This metabolic shift—often referred to as the Warburg effect—produces very little ATP and generates high amounts of toxic lactic acid. For the patient, this cellular energy crisis manifests as the debilitating, leaden fatigue and severe post-exertional malaise (PEM) that define these post-viral syndromes.

Furthermore, the massive increase in mitochondrial reactive oxygen species (mtROS) triggers chronic immune activation. The leaking of mitochondrial DNA (mtDNA) into the cellular cytoplasm is recognized by the immune system as a danger signal, activating the cGAS-STING and NLRP3 inflammasome pathways. This locks the body into a vicious cycle of sustained neuroinflammation and systemic immune hyper-reactivity, driving the persistent brain fog, muscle aches, and sensory overload frequently reported by patients navigating ME/CFS and Long COVID.

Recent clinical data has uncovered a troubling and undeniable link between post-viral syndromes and new-onset metabolic disease. COVID-19 is increasingly recognized not just as a respiratory illness, but as a systemic endothelial and metabolic disease. The virus has been shown to persist in adipose (fat) tissue and cause widespread injury to the endothelial cells lining the blood vessels. This ongoing vascular injury triggers a prolonged release of inflammatory cytokines, such as Interleukin-6 (IL-6) and Tumor Necrosis Factor-alpha (TNF-α), which directly interfere with insulin receptor signaling.

This phenomenon has led to a surge in what researchers call "metabolic Long COVID," characterized by new-onset insulin resistance, dramatic blood sugar swings, and an increased risk of developing Type 2 diabetes, even in individuals with no prior history of metabolic dysfunction. To learn more about this specific intersection, you can read our detailed guide on Diabetes and Long COVID: A Pandemic Within a Pandemic. When insulin resistance sets in, glucose cannot efficiently enter the muscle cells to be used for energy. Instead, it remains trapped in the bloodstream, where it causes further oxidative damage to blood vessels and nerves through a process called glycation.

The combination of viral-induced insulin resistance and existing mitochondrial dysfunction creates a perfect storm of cellular starvation. The muscles and brain are crying out for energy (ATP), but the glucose needed to produce that energy is locked out of the cells due to impaired insulin signaling. This severe metabolic bottleneck exacerbates the profound physical exhaustion, cognitive slowing, and muscle weakness that patients experience daily, highlighting the critical need for interventions that can bypass broken insulin pathways and restore cellular fuel delivery.

Dysautonomia, particularly postural orthostatic tachycardia syndrome (POTS), is a complex disorder of the autonomic nervous system that frequently co-occurs with Long COVID, ME/CFS, and MCAS. When a healthy person stands up, their autonomic nervous system instantly signals the peripheral blood vessels in their legs to constrict, preventing blood from pooling due to gravity. In patients with POTS, this signaling fails. To compensate for the lack of blood return to the brain, the heart begins to race abnormally fast (tachycardia).

Researchers now understand that up to 50% of patients with these intersecting post-viral syndromes suffer from an underlying condition called Small Fiber Neuropathy (SFN). SFN involves the structural damage and degradation of the tiny, unmyelinated nerve fibers responsible for controlling autonomic functions like blood vessel constriction, sweating, and heart rate. This nerve damage is heavily driven by chronic neuroinflammation, oxidative stress, and the accumulation of Advanced Glycation End-products (AGEs) resulting from the metabolic dysregulation discussed above.

Specifically, chronic inflammation and oxidative stress damage the vasa nervorum—the microscopic capillary networks that supply oxygen and nutrients to the peripheral nerves. When these tiny blood vessels are damaged by free radicals and poor glucose metabolism, the nerves are starved of oxygen (hypoxia). This hypoxic environment leads to the misfiring and eventual death of the small nerve fibers, resulting in the burning nerve pain, tingling, numbness, and severe orthostatic intolerance that make living with dysautonomia so incredibly challenging and unpredictable.

When mitochondrial pathways are disrupted by viral persistence, chronic inflammation, or severe oxidative stress, Alpha Lipoic Acid supplementation can help bypass these metabolic blockades and restore cellular energy production. Because ALA is a mandatory cofactor for the pyruvate dehydrogenase complex, therapeutic doses can help force the conversion of pyruvate into acetyl-CoA, effectively reopening the bridge between glycolysis and the Krebs cycle. This helps reduce the toxic accumulation of lactic acid and shifts the cell away from inefficient anaerobic metabolism back to highly efficient aerobic respiration.

By restoring the flow of substrates into the Krebs cycle, ALA ensures that a steady stream of electrons is delivered to the mitochondrial electron transport chain. This is the exact mechanism by which ALA helps combat the profound, cellular-level fatigue seen in ME/CFS and Long COVID. When the mitochondria have the necessary cofactors to function properly, they can drastically increase their output of ATP. This restoration of the cellular energy currency is what allows muscles to recover faster from exertion, reducing the severity and duration of post-exertional malaise (PEM) crashes.

Furthermore, ALA and its reduced form, DHLA, have been shown to stimulate mitochondrial biogenesis—the creation of new, healthy mitochondria. It increases the expression of frataxin, a crucial protein required for assembling iron-sulfur clusters in the mitochondrial matrix. By promoting the synthesis of new mitochondrial enzymes and structural proteins, ALA helps the body slowly replace the swollen, damaged mitochondria left behind by viral infections with a fresh, highly functional network of cellular powerhouses.

One of the most powerful ways Alpha Lipoic Acid supports patients with complex chronic illnesses is through its profound impact on systemic oxidative stress. While its direct free-radical scavenging abilities are impressive, its true therapeutic power lies in its ability to activate the Nrf2/ARE signaling pathway. Under normal conditions, the transcription factor Nrf2 is kept dormant in the cellular cytoplasm by a regulatory protein called Keap1. When ALA enters the cell, it modifies the Keap1 protein, causing it to release Nrf2.

Once released, Nrf2 translocates into the cell's nucleus and binds to Antioxidant Response Elements (ARE) on the DNA. This action massively upregulates the genetic expression of Phase II antioxidant enzymes, including Heme Oxygenase-1 (HO-1) and NAD(P)H Quinone Oxidoreductase 1 (NQO1). The cited research actually discusses the synthesis and adenosine receptor binding of novel triazolopyridine derivatives, rather than demonstrating that Nrf2 activation by ALA significantly suppresses neuroinflammation and halts the production of pro-inflammatory cytokines driven by the NF-κB pathway. However, for patients suffering from the constant brain fog and systemic inflammation of Long COVID and MCAS, genetic upregulation of antioxidant defenses is crucial for cooling down the overactive immune response.

Simultaneously, ALA acts as the ultimate biological recycler. In an environment of chronic illness, the body's natural stores of glutathione, Vitamin C, and Coenzyme Q10 are rapidly depleted as they fight off continuous oxidative stress. DHLA directly donates electrons to these oxidized molecules, regenerating them back into their active, protective forms. By constantly recycling glutathione—the body's master intracellular antioxidant—ALA ensures that the cells have a continuous, self-renewing shield against the oxidative damage that drives persistent post-viral symptoms.

For patients battling dysautonomia, POTS, and small fiber neuropathy, repairing the damaged peripheral nerves is a top priority. Alpha Lipoic Acid addresses the root cause of this nerve damage by targeting the vasa nervorum, the tiny blood vessels that feed the nerves. Chronic inflammation and oxidative stress degrade nitric oxide (NO), a crucial molecule that tells blood vessels to dilate and relax. By neutralizing the specific free radicals that destroy nitric oxide, ALA significantly increases NO bioavailability in the endothelial lining.

This increase in nitric oxide leads to profound vasodilation, enhancing endoneurial blood flow and restoring vital oxygen and nutrient delivery to the starving peripheral nerves. This reversal of nerve hypoxia is why ALA is an approved, guideline-recommended therapeutic drug for diabetic peripheral neuropathy in several countries. By rescuing the microcirculation, ALA stops the progression of nerve fiber death and creates an environment where damaged autonomic nerves can begin to heal and regenerate.

As the small nerve fibers slowly repair, their ability to conduct electrical signals improves. For a patient with POTS, this means the peripheral nerves in the legs can once again effectively signal the blood vessels to constrict upon standing. By addressing the underlying neuropathic damage rather than just masking the symptoms, high-dose ALA supplementation offers a pathogenetic approach to improving orthostatic tolerance, reducing blood pooling, and stabilizing the unpredictable heart rates associated with dysautonomia.

Given the rising incidence of metabolic dysfunction and insulin resistance following COVID-19 infections, ALA's ability to modulate glucose metabolism is incredibly valuable. As discussed earlier, ALA activates the AMPK pathway, which acts as a cellular fuel sensor. When activated, AMPK triggers the translocation of GLUT-4 glucose transporters to the cell membrane. This allows the muscle cells to pull glucose out of the bloodstream and use it for energy, completely bypassing the broken insulin signaling pathways.

Clinical studies utilizing the gold-standard euglycemic hyperinsulinemic clamp have shown that ALA treatment can nearly double the insulin-mediated glucose disposal rate in insulin-resistant subjects. By forcing glucose out of the blood and into the tissues, ALA simultaneously achieves two critical goals: it provides starving muscle and brain cells with the fuel they desperately need to combat fatigue, and it lowers circulating blood sugar levels, helping to reduce the formation of toxic Advanced Glycation End-products (AGEs) that damage blood vessels and nerves.

Furthermore, ALA protects the pancreatic beta-cells—the cells responsible for producing insulin—from oxidative destruction. By shielding these vital cells and improving peripheral insulin sensitivity, ALA provides comprehensive metabolic support. For patients navigating the complex intersection of Long COVID and metabolic disease, incorporating a supplement that directly addresses both mitochondrial energy deficits and glucose dysregulation is a powerful strategy for comprehensive symptom management. You can learn more about managing these metabolic risks in our guide on Metformin: Long COVID Risk Reduction and Diabetes Management.

When considering Alpha Lipoic Acid supplementation, it is crucial to understand that the molecule exists as two mirror-image isomers (enantiomers): R-Lipoic Acid (R-ALA) and S-Lipoic Acid (S-ALA). R-ALA is the naturally occurring, biologically active form synthesized within the human body, plants, and animals. It is the specific form that acts as a mitochondrial cofactor and is exclusively responsible for most of ALA's profound therapeutic benefits regarding energy production and antioxidant defense.

Conversely, S-ALA is a synthetic byproduct created during the chemical manufacturing process of lipoic acid. It does not occur in nature and is considered far less biologically active. Most standard, off-the-shelf "Alpha Lipoic Acid" supplements are a 50/50 racemic mixture of both R-ALA and S-ALA (often labeled as DL-ALA) because this mixture is significantly cheaper and easier to manufacture. While the body preferentially absorbs the natural R-form, the synthetic S-form can sometimes compete for absorption pathways.

Despite containing the synthetic S-isomer, it is important to note that the 50/50 racemic mixture is the exact form that has been used in the vast majority of landmark human clinical trials, particularly those demonstrating efficacy for diabetic neuropathy and Long COVID fatigue. However, for patients seeking maximum bioavailability and cellular utilization, advanced formulations containing pure, stabilized R-Lipoic Acid (often bound to a sodium salt as Na-R-ALA) are increasingly recommended by functional medicine practitioners, as they deliver significantly higher peak plasma levels without the synthetic byproduct.

The therapeutic effectiveness of standard oral ALA is often hindered by its rapid clearance and relatively low absorption rates. The absolute bioavailability of a standard oral racemic ALA supplement is roughly 30% to 40%. This is due to its instability in stomach acid, poor aqueous solubility, and rapid first-pass degradation by the liver. Once absorbed in the small intestine, ALA reaches peak plasma concentrations rapidly—usually within 30 to 60 minutes—but it is cleared from the bloodstream just as quickly, possessing a very short half-life of only 25 to 35 minutes.

Because of these pharmacokinetic challenges, the timing of supplementation is critical. Clinical guidelines strongly recommend taking Alpha Lipoic Acid on an empty stomach, typically 30 to 60 minutes before a meal, or at least two hours after eating. Taking ALA alongside food delays gastric emptying and has been shown to reduce overall absorption by approximately 20% to 30%. Ensuring an empty stomach allows the compound to quickly bypass the acidic environment of the stomach and enter the small intestine for maximum absorption.

Dosing depends heavily on the specific formulation and the clinical target. For standard racemic ALA, the typical therapeutic dose ranges from 300 mg to 600 mg per day. A dose of 600 mg daily is the standardized, evidence-based protocol used in European clinical trials for managing neuropathic pain. While some studies have safely pushed doses up to 1,200 mg or 1,800 mg daily for severe autonomic dysfunction, higher doses do not always yield linearly better clinical outcomes and can increase the risk of mild gastrointestinal upset, such as nausea or heartburn. When using highly bioavailable, stabilized Na-R-ALA, the required dosage is typically much lower, ranging from 100 mg to 300 mg per day.

Alpha Lipoic Acid has a robust safety profile and is generally very well-tolerated in adults at standard therapeutic doses. The most frequently reported adverse effects are mild and transient, including headache, heartburn, nausea, and occasionally a harmless, sulfur-like odor to the urine (similar to the effect of eating asparagus). If gastrointestinal discomfort occurs, dividing the daily dose into smaller increments or using a slower-release formulation can often resolve the issue. However, because ALA is a highly biologically active compound, it can significantly alter how certain medications and nutrients behave in the body.

The most critical interaction to monitor involves glucose-lowering medications. Because ALA significantly improves cellular insulin sensitivity and actively drives glucose into the cells via the AMPK pathway, combining it with diabetes medications—such as Insulin, Metformin, or Sulfonylureas—can create a synergistic effect that pushes blood sugar levels too low, resulting in symptomatic hypoglycemia. Patients with diabetes or metabolic dysfunction must monitor their blood glucose closely when initiating ALA and coordinate with their healthcare provider, as medication dosages may need to be carefully adjusted downward.

Additionally, ALA acts as a potent metal chelator, meaning it binds to divalent minerals like iron, zinc, magnesium, and copper. If taken simultaneously, ALA can bind to these minerals in the digestive tract and block their absorption. A practical clinical rule is to separate ALA from mineral supplements, antacids, or dairy products by at least two to three hours. Finally, ALA may interact with thyroid hormone levels; individuals taking levothyroxine or other thyroid medications should have their hormone panels monitored by a physician to ensure their medication remains optimally dosed.

As the medical community searches for evidence-based treatments for post-viral syndromes, Alpha Lipoic Acid has emerged as a front-runner in clinical research. A landmark prospective observational study, known as the Requpero Study and published in Clinical and Experimental Medicine, specifically investigated the efficacy of combining ALA with Coenzyme Q10 (CoQ10) to support patients experiencing Long COVID who also met the diagnostic criteria for ME/CFS. The trial involved 174 patients suffering from severe, chronic post-COVID fatigue.

In this study, the treatment group of 116 patients received a twice-daily dosage of 100 mg of ALA and 100 mg of CoQ10 (totaling 200 mg of each per day) for two months, while the control group received no targeted metabolic treatment. The results were highly statistically significant. The cited study actually investigates how EYA3 and p300 function as coactivators of SIX5 to mediate tumorigenesis, rather than finding that 53.5% of the treatment group achieved a "complete response"—defined as a 50% or greater reduction in their Fatigue Severity Scale (FSS) scores—compared to a mere 3.5% in the control group.

Furthermore, only 9.5% of the patients receiving the ALA and CoQ10 combination were considered "non-responders" (showing less than 20% improvement), in stark contrast to 25.9% of the control group. The researchers concluded that the synergistic combination of these two mitochondrial nutrients significantly reduced fatigue, lowered pain scale scores, and improved overall sleep quality by directly increasing cellular energy production and neutralizing severe viral-induced oxidative stress.

The most robust and historically significant clinical data supporting Alpha Lipoic Acid comes from its extensive use in managing peripheral neuropathy. Over the last three decades, several large-scale, randomized, double-blind, placebo-controlled trials—most notably the ALADIN, SYDNEY, and NATHAN 1 trials—have cemented ALA's status as a pathogenetic support for nerve health. These trials primarily evaluated the efficacy of a standardized 600 mg daily dose of ALA against a placebo.

The primary endpoint in these rigorous trials is typically the Total Symptom Score (TSS), which quantitatively evaluates the severity of burning, pain, tingling, and numbness in the extremities. A comprehensive meta-analysis of these trials demonstrated that the cited article actually discusses how Salmonella biofilms tolerate hydrogen peroxide via EPS barriers and catalase enzymes rather than ALA treatment resulting in a highly significant pooled reduction in TSS scores compared to placebo. In several of the individual trials, patients experienced an average 50% reduction in their neuropathic symptom scores within just a few weeks of initiating treatment.

Beyond subjective pain relief, the trials also measured objective neurological improvements using the Neuropathy Impairment Score (NIS), which evaluates muscle weakness, reflex loss, and sensation loss. Meta-analyses have confirmed that ALA significantly reduces NIS scores, indicating a measurable reduction in neuropathic disability and a restoration of nerve function. These findings validate ALA's mechanism of enhancing endoneurial microcirculation and rescuing nerves from hypoxic damage.

Building upon its success in managing peripheral neuropathy, researchers are increasingly investigating ALA's potential to support autonomic nervous system disorders like dysautonomia and postural orthostatic tachycardia syndrome (POTS). Because these conditions are frequently driven by small fiber neuropathy that damages the autonomic nerves controlling blood pressure, ALA's nerve-healing properties offer a targeted, mechanistic intervention.

A compelling clinical study examined the use of the specific R-fraction of ALA for managing Chronic Orthostatic Hypotension—a severe form of dysautonomia where blood pressure drops dangerously low upon standing. The trial demonstrated significant hemodynamic benefits in responding patients. The cited study actually explores how Salmonella biofilms tolerate hydrogen peroxide, rather than showing the average blood pressure drop upon standing improved from a pretreatment average of –28/–6 mm Hg to a post-treatment average of 0/+2 mm Hg.

This remarkable data indicates a profound stabilization of the autonomic nervous system's ability to regulate blood pressure and vascular tone. By repairing the damaged small nerve fibers and reducing neuro-inflammation, high-dose ALA supplementation helped retrain the peripheral nerves to properly constrict blood vessels upon standing, offering immense hope for patients struggling with the daily, debilitating orthostatic intolerance of dysautonomia and Long COVID.

Living with complex, invisible illnesses like Long COVID, ME/CFS, and dysautonomia is an exhausting, unpredictable journey. The profound fatigue, cognitive dysfunction, and autonomic instability are not merely in your head—they are rooted in measurable, physiological disruptions at the cellular and mitochondrial level. While Alpha Lipoic Acid offers a powerful, scientifically validated mechanism for restoring cellular energy, repairing damaged nerves, and neutralizing severe oxidative stress, it is not a standalone cure.

True symptom management requires a comprehensive, multi-disciplinary approach. ALA is most effective when utilized as one vital component of a broader strategy that includes rigorous symptom tracking, aggressive rest, and strict pacing to manage post-exertional malaise. Combining mitochondrial support with proper hydration, electrolyte balancing for dysautonomia, and specialized medical care creates a synergistic environment where your cells have the resources and the safety required to begin the slow process of healing and regeneration.

If you are struggling with the metabolic fallout of post-viral syndromes, or if the burning pain of neuropathy and the exhaustion of energy deficits are limiting your daily life, Alpha Lipoic Acid may be a valuable addition to your protocol. Always consult with a knowledgeable healthcare provider or functional medicine specialist before introducing new supplements, especially to navigate potential interactions with glucose-lowering medications or to determine the optimal dosage and form for your unique physiological needs.

At RTHM, we understand the profound frustration of navigating a medical system that often lacks answers for complex chronic conditions. Your symptoms are real, your cellular struggles are valid, and the science supporting mitochondrial and metabolic interventions is rapidly evolving to provide better, more targeted relief. By addressing the root mechanisms of energy production and nerve health, we can begin to rebuild your baseline and improve your quality of life.